EpiShuttle approved for use in the Australian market

EpiGuard has announced that the EpiShuttle has been approved by the Therapeutic Goods Administration (TGA) and is now fully available for use in the Australian market.

TGA is Australia’s regulatory authority for therapeutic goods such as medicines, medical devices and diagnostic tests. This approval adds to the the EpiShuttle isolation and transport system.

Michael Eimstad, CEO at EpiGuard, said: “Even though the EpiShuttle has been with Royal Australian Air Force (RAAF) for some time now, we are happy to see that the safe isolation and transport system now fully available to the civil Australian market.”

EpiGuard can now expand its market presence and provide a valuable solution to healthcare providers in Australia. The EpiShuttle will be an asset to medical providers, allowing them to transport infectious patients safely and efficiently in emergency situations.

Eimstad explained: “We have all experienced how contagious viral diseases are and how they occur more frequently. We know that the EpiShuttle is the best, safest, and most efficient way to transport contagious patients by air.

“The EpiShuttle is finally available to front-running Australian players like CareFlight in their H145, and especially LifeFlight Australia, with their Challenger 604 in service, which is the same aircraft as FAI air ambulance recently received their supplementary type certification (STC) by the European Union Aerospace Safety Agency (EASA) on. Same goes for MedSTAR and their Bell412 which is the helicopter the Royal Norwegian Air Force fitted for use with the EpiShuttle.

“Furthermore, Toll Ambulance Rescue can benefit from both the Northern Norway Regional Health Authority and Abu Dhabi Police’s experience from using the EpiShuttle in the AW139. Also, the Royal Flying Doctor Service (RFDS) may benefit a lot from Pilatus Aircraft Ltd’s own integration of the EpiShuttle, into their four medevac PC-24s.”